$9.01
2.28% yesterday
NYSE, Aug 11, 10:06 pm CET
ISIN
US68622V1061
Symbol
OGN

Organon & Co. Stock price

$9.01
-0.93 9.36% 1M
-5.94 39.73% 6M
-5.91 39.61% YTD
-10.45 53.70% 1Y
-22.68 71.57% 3Y
-24.24 72.90% 5Y
-24.24 72.90% 10Y
-24.24 72.90% 20Y
NYSE, Closing price Mon, Aug 11 2025
-0.21 2.28%

Key metrics

Basic
Market capitalization
$2.3b
Enterprise Value
$10.6b
Net debt
$8.3b
Cash
$599.0m
Shares outstanding
260.0m
Valuation (TTM | estimate)
P/E
3.3 | 2.3
P/S
0.4 | 0.4
EV/Sales
1.7 | 1.7
EV/FCF
22.1
P/B
3.2
Dividends
DPS
$1.12
Yield 1Y | 5Y
12.4% | 3.1%
Growth 1Y | 5Y
0.0% | -
Payout 1Y | 3Y
33.6% | 30.8%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$6.3b | $6.3b
EBITDA
$1.7b | $2.0b
EBIT
$1.4b | $1.8b
Net Income
$700.0m | $1.0b
Free Cash Flow
$482.0m
Growth (TTM | estimate)
Revenue
-1.0% | -1.9%
EBITDA
6.3% | 13.6%
EBIT
2.4% | 19.5%
Net Income
-30.0% | 17.4%
Free Cash Flow
-38.8%
Margin (TTM | estimate)
Gross
56.3%
EBITDA
26.7% | 31.5%
EBIT
21.6%
Net
11.1% | 16.1%
Free Cash Flow
7.7%
Financial Health
Equity Ratio
3.6%
Return on Equity
183.1%
ROCE
12.7%
ROIC
12.3%
Debt/Equity
12.1
More
EPS
$2.7
FCF per Share
$1.9
Short interest
7.5%
Employees
10k
Rev per Employee
$640.0k
Show more

Is Organon & Co. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Organon & Co. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Organon & Co. forecast:

3x Buy
20%
4x Hold
27%
8x Sell
53%

Analyst Opinions

15 Analysts have issued a Organon & Co. forecast:

Buy
20%
Hold
27%
Sell
53%

Financial data from Organon & Co.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
6,281 6,281
1% 1%
100%
- Direct Costs 2,747 2,747
5% 5%
44%
3,534 3,534
5% 5%
56%
- Selling and Administrative Expenses 1,765 1,765
6% 6%
28%
- Research and Development Expense 432 432
13% 13%
7%
1,678 1,678
6% 6%
27%
- Depreciation and Amortization 319 319
27% 27%
5%
EBIT (Operating Income) EBIT 1,359 1,359
2% 2%
22%
Net Profit 700 700
30% 30%
11%

In millions USD.

Don't miss a Thing! We will send you all news about Organon & Co. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Organon & Co. Stock News

Negative
Seeking Alpha
6 days ago
Organon & Co.'s shrinking revenues, heavy debt, and slashed dividend make it an unattractive investment despite its low valuation metrics. The Established Brands division is in decline, and new products like Emgality and VTAMA are not offsetting losses from older drugs. Women's Health and Biosimilars show some growth, but not enough to reverse the overall negative trend or justify optimism.
Neutral
The Motley Fool
6 days ago
Organon (OGN) Fiscal Q2 Revenue Beats 1%
Neutral
Seeking Alpha
7 days ago
Organon & Co. (NYSE:OGN ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Jennifer Halchak - Corporate Participant Juan Camilo Arjona Ferreira - Executive VP, Head of Research & Development and Chief Medical Officer Kevin Ali - CEO & Director Matthew M. Walsh - Executive VP & CFO Conference Call Participants Alexandra Doering von Riesemann - Piper Sandler & Co., ...
More Organon & Co. News

Company Profile

Organon & Co. is a science based global pharmaceutical company that develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020 and is headquartered in Jersey City, NJ.

Head office United States
CEO Kevin Ali
Employees 10,000
Founded 2020
Website www.organon.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today